Ocular Therapeutix Grants Equity to Nine New Hires Under Nasdaq Rules

Ocular Therapeutix, Inc. (NASDAQ: OCUL) granted inducement equity awards to nine newly hired non-executive employees effective September 14, 2026. The company disclosed the grants in a report filed with the Nasdaq, citing Listing Rule 5635(c)(4). These awards were specifically issued as a material inducement for each recipient to accept employment with the biopharmaceutical firm.

The equity package consists of 64,850 non-statutory stock options and 21,350 restricted stock units (RSUs), totaling 86,200 shares of Ocular common stock. The options carry an exercise price of $10.72 per share, matching the closing price on the Nasdaq Global Market on the grant date. This structure allows the company to retain talent without immediate cash outlay while tying future ownership to continued service.

Vesting schedules tie equity to retention

The stock option awards have a ten-year term. Vesting follows a four-year schedule, with 25% of the original share count unlocking on the one-year anniversary of the grant. The remaining options vest in equal monthly installments over the subsequent three years. Each tranche is contingent on the recipient’s continued service with Ocular through the applicable vesting dates.

The restricted stock units follow a distinct three-year vesting timeline. These awards vest in equal annual installments on the first, second, and third anniversaries of the grant date. Like the options, the RSUs are subject to the recipient’s continued employment with the company through each respective vesting date. This staggered approach aligns long-term employee incentives with the company’s operational stability.

Pipeline context for the hiring push

Ocular Therapeutix is an integrated biopharmaceutical company focused on retinal disease treatments. Its lead investigational product, AXPAXLI (OTX-TKI), is an axitinib intravitreal hydrogel currently in Phase 3 clinical trials. The drug targets wet age-related macular degeneration and diabetic retinal disease, including non-proliferative diabetic retinopathy. The company utilizes its proprietary ELUTYX bioresorbable hydrogel technology for this formulation.

The pipeline also includes DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following surgery. Another candidate, OTX-TIC, is a travoprost intracameral hydrogel that completed a Phase 2 trial for open-angle glaucoma. The company is currently evaluating next steps for the OTX-TIC program. The recent hiring under the 2019 Inducement Stock Incentive Plan supports these ongoing clinical and commercial efforts.

Regulatory compliance drives the disclosure

The grants were made under Ocular’s 2019 Inducement Stock Incentive Plan. Nasdaq Listing Rule 5635(c)(4) permits companies to issue equity awards to new employees without a shareholder vote, provided the awards serve as a material inducement for the hire. Ocular disclosed these specific grants to maintain transparency with investors and comply with exchange listing requirements. The awards are subject to the terms of the individual award agreements and the overarching plan.